These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 8960658

  • 1. [Successful treatment of acute non-lymphoblastic leukemia from myelodysplastic syndrome by combination of human macrophage colony-stimulating factor (M-CSF) and low dose cytosine arabinoside: M-CSF-induced proliferation and tyrosine phosphorylation in leukemic blasts].
    Hagiwara S, Yuo A, Nagai M, Takezako N, Soda Y, Miwa A, Togawa A, Takaku F.
    Rinsho Ketsueki; 1996 Nov; 37(11):1259-64. PubMed ID: 8960658
    [Abstract] [Full Text] [Related]

  • 2. [In vitro growth and clinical response of leukemia cells to macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-CSF) in acute leukemia].
    Takeyama H, Kajiguchi T, Miyata Y, Saito M.
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):873-8. PubMed ID: 10897214
    [Abstract] [Full Text] [Related]

  • 3. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia.
    Cannistra SA, Groshek P, Griffin JD.
    Leukemia; 1989 May; 3(5):328-34. PubMed ID: 2654494
    [Abstract] [Full Text] [Related]

  • 4. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
    Fukuhara T, Miyake T, Maekawa I, Kurosawa M, Suzuki S, Noto S, Mori A, Chiba K, Toyoshima T, Hirano T, Morioka M, Tsutsumi Y, Okabe M, Kakinoki Y.
    Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
    [Abstract] [Full Text] [Related]

  • 5. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

  • 6. Effect of the chimeric soluble granulocyte colony-stimulating factor receptor on the proliferation of leukemic blast cells from patients with acute myeloblastic leukemia.
    Asano Y, Yokoyama T, Shibata S, Kobayashi S, Shimoda K, Nakashima H, Okamura S, Niho Y.
    Cancer Res; 1997 Aug 15; 57(16):3395-7. PubMed ID: 9270003
    [Abstract] [Full Text] [Related]

  • 7. Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic phase.
    Im T, Yamane T, Mugitani A, Hiyoshi M, Park K, Tatsumi N.
    Int J Hematol; 1994 Oct 15; 60(3):215-23. PubMed ID: 7532031
    [Abstract] [Full Text] [Related]

  • 8. [Hypoplastic leukemia which achieved remission with administration of M-CSF along with low dose ara-C].
    Kamimura N, Nakamura T.
    Rinsho Ketsueki; 1993 May 15; 34(5):662-6. PubMed ID: 8315838
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.
    Leuk Res; 2008 Dec 15; 32(12):1830-6. PubMed ID: 18571721
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 15; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 14. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemias and myelodysplastic syndromes.
    Tambone Reyes M, Bonaccorso R, Gebbia V, Tinnirello D, Di Salvo V, Ciulla A, Di Marco P, Mansueto S, Citarrella P.
    J Chemother; 1989 Jul 15; 1(4 Suppl):1276-8. PubMed ID: 16312864
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sequential promotion of normal and leukemic hemopoiesis by recombinant human granulocyte colony-stimulating factor during the course of myelodysplastic syndrome.
    Ueda T, Kawai Y, Sugiyama T, Takeuchi N, Yoshida A, Iwasaki H, Wano Y, Tsutani H, Kamada N, Nakamura T.
    Int J Hematol; 1993 Dec 15; 59(1):47-52. PubMed ID: 7512833
    [Abstract] [Full Text] [Related]

  • 18. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
    Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Giebel S, Skotnicki AB, Piatkowska-Jakubas B, Kuliczkowski K, Kiełbiński M, Zawilska K, Kłoczko J, Wrzesień-Kuś A, Polish Adult Leukemia Group.
    Eur J Haematol; 2008 Feb 15; 80(2):115-26. PubMed ID: 18076637
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia.
    Hubeek I, Litvinova E, Peters GJ, Broekhuizen R, Haarman EG, Huismans DR, Cloos J, Zwaan CM, Fleischhack G, Creutzig U, Kaspers GJ.
    Int J Oncol; 2004 Dec 15; 25(6):1823-9. PubMed ID: 15547723
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.